Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...

Crocs designs, develops, manufactures and distributes casual footwear and accessories for men, women and children ... Dupixent and Eylea. Dupixent is an eczema treatment whose rights Regeneron ...

Welcome to the Winter 2025 issue of “FCA Enforcement & Compliance Digest,” our quarterly newsletter in which we compile essential updates on ...

which includes nine products SELARSDI is approved for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and pediatric Duquesne Family Office's ...

They all had severe disease and a high treatment burden with an average of 10 injections with Eylea (aflibercept), a widely-used VEGF inhibitor sold by Bayer and Regeneron, in the last 12 months.

Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...

Regenxbio Inc. (RGNX) reported its earnings for the fourth quarter of 2024, surpassing expectations with an earnings per share (EPS) of -1.01, compared to the forecasted -1.13. Despite a revenue miss, ...

Retatrutide is an new drug that has shown promise in the treatment of obesity and type 2 diabetes. Retatrutide is a type of multi-receptor agonist that targets multiple hormonal pathways involved in ...